PKN2 (Protein Kinase N2)
A serine/threonine-protein kinase involved in cell signaling, cytoskeletal regulation, and cancer progression.
Gene Information Card
| Symbol | PKN2 |
|---|---|
| Full Name | Protein Kinase N2 |
| Gene Type | protein-coding |
| Chromosomal Location | 1p22.2 |
| NCBI Gene ID | 5586 ncbi.nlm.nih.gov/gene/5586 |
| Ensembl ID | ENSG00000165246 |
| UniProt ID | Q16513 |
| OMIM ID | 601032 |
| HGNC ID | 9405 |
| Aliases | PRK2, PAK2, PKN2, STK7 |
Description
PKN2 (Protein Kinase N2) is a serine/threonine-protein kinase that belongs to the protein kinase C (PKC) superfamily. It is activated by Rho family small GTPases and plays critical roles in cytoskeletal reorganization, cell adhesion, migration, and proliferation. PKN2 is implicated in various cancers and developmental processes.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Cancer (multiple types) | PKN2 overexpression or mutation alters Rho signaling and cell motility, promoting tumor invasion and metastasis. | COSMIC, ClinVar |
| Cardiovascular disease | PKN2 regulates smooth muscle contraction and endothelial barrier function; dysregulation linked to vascular pathology. | NCBI Gene, UniProt |
| Developmental disorders | PKN2 mutations affect neuronal migration and cytoskeletal dynamics, potentially contributing to neurodevelopmental phenotypes. | OMIM |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 12.5 | Medium |
| Heart | 8.3 | Low |
| Lung | 15.2 | Medium |
| Liver | 6.1 | Low |
| Kidney | 10.4 | Medium |
| Testis | 18.7 | High |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 14.2 | Cervical cancer cell line |
| A549 | 11.8 | Lung cancer cell line |
| MCF7 | 9.5 | Breast cancer cell line |
| HEK293 | 13.0 | Embryonic kidney cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1234C>T (p.Arg412Cys) | Missense | <0.1% | Altered kinase activity; potential gain-of-function |
| c.567_568del (p.Glu190fs) | Frameshift | <0.01% | Loss of function; truncated protein |
| c.2101G>A (p.Gly701Arg) | Missense | <0.05% | Unknown; located in kinase domain |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense mutations that truncate the kinase domain or disrupt catalytic activity.
Gain of Function (GOF)
Missense mutations in the kinase domain that enhance catalytic activity or alter substrate specificity.
Dominant Negative (DN)
Mutations that produce a kinase-dead protein capable of interfering with wild-type PKN2 signaling.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Rho GTPase cycle (R-HSA-194840)
• Signaling by Rho family GTPases (R-HSA-194315)
• Regulation of actin cytoskeleton (KEGG:04810)
• Focal adhesion (KEGG:04510)
Protein Summary
PKN2 is a 984-amino-acid serine/threonine kinase with an N-terminal regulatory region containing a C2-like domain and a C-terminal catalytic kinase domain. It is activated by binding to RhoA, Rac1, or Cdc42, leading to autophosphorylation and phosphorylation of downstream targets such as vimentin, tau, and myosin phosphatase. PKN2 is ubiquitously expressed with highest levels in testis and brain. Its dysregulation is associated with cancer cell invasion, cardiovascular dysfunction, and developmental abnormalities.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PKN2 Knockout HEK293 Cell Line | EDJ-KQ848 | Human | 5586 | Details Get a Quote |
| PKN2 Knockout HCT 116 Cell Line | EDJ-KQ18362 | Human | 5586 | Details Get a Quote |
| PKN2 Knockout A-549 Cell Line | EDJ-KQ19639 | Human | 5586 | Details Get a Quote |
| PKN2 Knockout HeLa Cell Line | EDJ-KQ19640 | Human | 5586 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
